Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

REVIVA PHARMACEUTICALS HOLDINGS, INC.

(RVPH)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Reviva Pharmaceuticals : Maxim Group Initiates Reviva Pharmaceuticals at Buy Rating With $10 Price Target

07/26/2021 | 11:18am EDT


© MT Newswires 2021
All news about REVIVA PHARMACEUTICALS HOLDINGS, INC.
09/15Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small C..
GL
09/02REVIVA PHARMACEUTICALS : to Present at the H.C. Wainwright 23rd Annual Global In..
AQ
08/16REVIVA PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Recen..
PU
08/16REVIVA PHARMACEUTICALS HOLDINGS, INC : Results of Operations and Financial Condi..
AQ
08/16REVIVA PHARMACEUTICALS : Reports Second Quarter 2021 Financial Results and Recen..
AQ
08/16Reviva Pharmaceuticals Holdings, Inc. Announces Earnings Results for the Seco..
CI
08/16REVIVA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
08/16Reviva Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Second..
CI
07/26REVIVA PHARMACEUTICALS : Maxim Group Initiates Reviva Pharmaceuticals at Buy Rat..
MT
06/28Reviva Added to Russell Microcap® Index
GL
More news
Analyst Recommendations on REVIVA PHARMACEUTICALS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -11,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -5,29x
Yield 2021 -
Capitalization 59,8 M 59,8 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 5
Free-Float 59,7%
Chart REVIVA PHARMACEUTICALS HOLDINGS, INC.
Duration : Period :
Reviva Pharmaceuticals Holdings, Inc. Technical Analysis Chart | RVPH | US76152G1004 | MarketScreener
Technical analysis trends REVIVA PHARMACEUTICALS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 4,47 $
Average target price 14,50 $
Spread / Average Target 224%
EPS Revisions
Managers and Directors
Laxminarayan Bhat President, Chief Executive Officer & Director
Narayan Prabhu Chief Financial Officer
Parag Phoolchand Saxena Chairman
Marcus Cantillon Chief Medical Officer
Richard A. Margolin Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REVIVA PHARMACEUTICALS HOLDINGS, INC.-48.89%60
MODERNA, INC.311.65%173 588
LONZA GROUP AG32.35%60 074
IQVIA HOLDINGS INC.43.07%49 116
CELLTRION, INC.-23.26%31 904
SEAGEN INC.-10.81%28 420